Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019.

OBJECTIVES

Omadacycline was tested against 7000 bacterial isolates collected prospectively from medical centres in the USA during 2019.

METHODS

Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines.

RESULTS

Omadacycline was active against: Staphylococcus aureus (MIC, 0.12/0.25 mg/L; 98.3% susceptible), including methicillin-resistant S. aureus (MRSA); Enterococcus faecalis (MIC, 0.06/0.25 mg/L; 100.0% susceptible), including vancomycin-resistant enterococci (VRE); Streptococcus pneumoniae (MIC, 0.06/0.06 mg/L; 99.8% susceptible); viridans group streptococci, including Streptococcus anginosus group (MIC, 0.03/0.06 mg/L; 100.0% susceptible); β-haemolytic streptococci, including Streptococcus pyogenes (MIC, 0.06/0.12 mg/L; 99.2% susceptible); Enterobacterales (MIC, 1/8 mg/L; 86.9% inhibited at ≤4 mg/L), including Escherichia coli (MIC, 0.5/2 mg/L; 99.6% inhibited at ≤4 mg/L); Enterobacter cloacae (MIC, 2/4 mg/L; 98.5% susceptible); Klebsiella pneumoniae (MIC, 1/4 mg/L; 93.2% susceptible); Acinetobacter baumannii (MIC, 0.5/4 mg/L; 90.8% inhibited at ≤4 mg/L); Haemophilus influenzae (MIC, 0.5/1 mg/L; 100.0% susceptible); and Moraxella catarrhalis (MIC, ≤0.12/0.25 mg/L).

CONCLUSION

The 2019 in vitro activity of omadacycline against key Gram-positive and Gram-negative pathogens has not changed compared with the prior 3 years of surveillance in the SENTRY Antimicrobial Surveillance Program. Omadacycline merits further study in serious infections where resistant pathogens may be encountered.